Estrella Immunopharma Files Routine 8-K on Jan 30
Ticker: ESLAW · Form: 8-K · Filed: Jan 30, 2024 · CIK: 1844417
Complexity: simple
Sentiment: neutral
Topics: compliance, 8-K, corporate-governance
TL;DR
**Estrella Immunopharma filed a standard 8-K, no major news.**
AI Summary
Estrella Immunopharma, Inc. filed an 8-K on January 30, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing, under SEC File Number 001-40608, indicates standard reporting for a public company and does not disclose any specific new material events or financial changes. For investors, this means there's no immediate new information that would drastically alter their investment thesis, but it confirms the company's ongoing compliance with SEC reporting requirements.
Why It Matters
This filing is a routine compliance update, indicating Estrella Immunopharma, Inc. is meeting its regulatory obligations, which is a baseline expectation for any publicly traded company.
Risk Assessment
Risk Level: low — This 8-K is a routine filing and does not contain any information that would indicate a change in risk level for the company.
Analyst Insight
A smart investor would note this as a routine compliance filing, confirming the company's adherence to regulatory requirements, but would not expect any immediate market-moving news from this specific document. Further research into the company's core business and previous filings would be necessary for investment decisions.
Key Numbers
- 001-40608 — SEC File Number (Identifies Estrella Immunopharma's registration with the SEC.)
- 2024-01-30 — Date of Report (Indicates the specific date the event was reported.)
- 0.0001 — Common Stock Par Value (The nominal value per share of common stock for ESLA.)
- 11.50 — Warrant Exercise Price (The price at which each whole warrant can be exercised for one share of common stock.)
Key Players & Entities
- Estrella Immunopharma, Inc. (company) — the registrant filing the 8-K
- TradeUP Acquisition Corp. (company) — former name of Estrella Immunopharma, Inc.
- January 30, 2024 (date) — date of earliest event reported and filing date
- 001-40608 (dollar_amount) — SEC File Number for Estrella Immunopharma, Inc.
- 5858 Horton Street, Suite 370, Emeryville, California, 94608 (company) — business address of Estrella Immunopharma, Inc.
FAQ
What is the purpose of this 8-K filing by Estrella Immunopharma, Inc.?
This 8-K filing by Estrella Immunopharma, Inc. on January 30, 2024, is a 'Current Report' pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits.' It serves as a routine compliance update.
When was the earliest event reported in this filing?
The date of the earliest event reported in this filing is January 30, 2024, which is also the filing date.
What was the former name of Estrella Immunopharma, Inc.?
The former name of Estrella Immunopharma, Inc. was TradeUP Acquisition Corp., with the name change occurring on February 4, 2021.
What is the par value of Estrella Immunopharma, Inc.'s common stock?
The par value of Estrella Immunopharma, Inc.'s common stock is $0.0001 per share, as indicated by 'ESLA:CommonStockParValue0.0001PerShareMember' in the filing.
What is the exercise price for Estrella Immunopharma, Inc.'s warrants?
Each whole warrant for Estrella Immunopharma, Inc. is exercisable for one share of common stock at an exercise price of $11.50, as stated in 'ESLA:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member'.
Filing Stats: 502 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-01-30 11:29:52
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ESLA The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 ESLAW The Nasdaq Stock Market LLC
- $1 million — s authorized share repurchases of up to $1 million of its common stock. The authorization
Filing Documents
- ea192451-8k_estrella.htm (8-K) — 30KB
- ea192451ex99-1_estrella.htm (EX-99.1) — 7KB
- 0001213900-24-007723.txt ( ) — 254KB
- esla-20240130.xsd (EX-101.SCH) — 4KB
- esla-20240130_def.xml (EX-101.DEF) — 26KB
- esla-20240130_lab.xml (EX-101.LAB) — 36KB
- esla-20240130_pre.xml (EX-101.PRE) — 25KB
- ea192451-8k_estrella_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events On January 30, 2024, Estrella Immunopharma, Inc. issued a press release announcing that its board of directors has authorized share repurchases of up to $1 million of its common stock. The authorization does not constitute a formal or binding commitment to make any share repurchases and the timing, amount and method of any share repurchases made pursuant to the authorization will be determined at a future date depending on market conditions and other factors. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Estrella Immunopharma, Inc. By: /s/ Cheng Liu Name: Dr. Cheng Liu Title: Chief Executive Officer Date: January 30, 2024 2